Anti-cancer compound and pharmaceutical composition containing the same
US-9221817-B2 · Dec 29, 2015 · US
Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
US10611730B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10611730-B2 |
| Application number | US-201615569263-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2016 |
| Priority date | Apr 29, 2015 |
| Publication date | Apr 7, 2020 |
| Grant date | Apr 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
First claim
Opening claim text (preview).
What is claimed: 1. A compound having the structure of Formula (IA), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, R 1a is H or F; R 1b is H; R 2 is halo or C 1-5 haloalkoxy; R 3 is CN, or oxadiazolyl optionally substituted with C 1-5 haloalkyl; R 4 is H; R 5 is H or halo; and R 6 is halo, C 1-5 haloalkoxy, cyclopropyl, C(CH 3 ) 2 CN, or —O—CH 2 -cyclopropyl. 2. A compound having the structure of Formula (IB), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, wherein R 1a is H or F; R 1b is H; R 2 is halo or C 1-5 haloalkoxy; R 3 is CN, or oxadiazolyl optionally substituted with C 1-5 haloalkyl; R 4 is H; R 5 is H or halo; and R 6 is halo, C 1-5 haloalkoxy, cyclopropyl, —C(CH 3 ) 2 CN, or —O—CH 2 -cyclopropyl. 3. A compound selected from the group consisting of: 5-(2,3-Dimethylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,6-Dimethylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-(o-Tolyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-(Trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Phenylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Isopropylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,6-Dimethoxyphenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Isopropoxyphenyl)-1,3-dihydrobenzimidazol-2-one; tert-Butyl 4-[2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)phenyl]piperazine-1-carboxylate; 5-(5-Chloro-2-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Fluoro-6-isopropoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-(Cyclopropylmethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Isobutoxy-6-methoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Isobutoxy-5-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(5-Chloro-2-isopropoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Chlorophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,5-Dichlorophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Chloro-5-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Chloro-6-methoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,5-Dimethylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-Isopropoxy-5-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2,6-Dichloro-3-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Phenoxyphenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-5-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Benzyloxy-6-fluoro-phenyl)-1,3-dihydrobenzimidazol-2-one; 3-Fluoro-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzaldehyde; 5-(2-Isopropoxy-6-methoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-[3-Chloro-2-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-4-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(trifluoromethoxy)phenyl]-6-tritio-1,3-dihydrobenzimidazol-2-one; 5-[2-Methoxy-4-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[3-Chloro-2-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Bromophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Chloro-6-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(4-Chloro-2,6-dimethyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 3-Methyl-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 4-Methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 4-Chloro-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 2-[2-(2-Oxo-1,3-dihydrobenzimidazol-5-yl)phenyl]acetonitrile; Methyl 3-chloro-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 2-chloro-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 4-chloro-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 3-methyl-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 2-methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 4-methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; Methyl 2-methoxy-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzoate; 5-(2,6-Dichlorophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,6-Dichloro-4-fluoro-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,4,6-Trichlorophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2,6-Difluorophenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Chloro-6-fluoro-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Fluoro-6-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-(2-Fluoro-6-methoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 3-Chloro-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 5-[2-Methyl-6-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Benzylphenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-Methyl-3-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-3-(trifluoromethyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 2-Isopropoxy-6-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 2-Bromo-6-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 5-(2-Chloro-3-methyl-phenyl)-1,3-dihydrobenzimidazol-2-one; 2-(2-Oxo-1,3-dihydrobenzimidazol-5-yl)-6-(trifluoromethyl)benzonitrile; 5-(2,3,6-Trichlorophenyl)-1,3-dihydrobenzimidazol-2-one; 2-Methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 2-Chloro-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzonitrile; 5-[2-Methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydrobenzimidazol-2-one; 6-[2-Methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3H-1,3-benzothiazol-2-one; 5-[3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-2-methyl-phenyl]-1,3-dihydrobenzimidazol-2-one; 6-[3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-2-methyl-phenyl]-3H-1,3-benzothiazol-2-one; 5-[2-Methyl-3-[5-(4-pyridyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,3-dihydrobenzimidazol-2-one; 6-[2-Chloro-6-(trifluoromethoxy)phenyl]-3H-1,3-benzothiazol-2-one; 6-(2-Isopropoxy-6-methoxy-phenyl)-3H-1,3-benzothiazol-2-one; N-Methyl-2-[2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-6-(trifluoromethyl)phenyl]acetamide; 2-Methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-N-phenyl-benzamide; N-Cyclopropyl-2-methyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzamide; N,N,2-Trimethyl-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)benzamide; 5-[2-Methyl-3-(morpholine-4-carbonyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 4-Chloro-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-N-phenyl-benzamide; 5-[2-Chloro-5-(pyrrolidine-1-carbonyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-5-(piperidine-1-carbonyl)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(2-furylmethylamino)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(3-furylmethylamino)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Isopropoxy-6-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-(Cyclopropylmethoxy)-6-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(cyclopropoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Chloro-6-isopropoxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(cyclopropylmethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; (±)-5-[2-Chloro-6-[(2,2-difluorocyclopropyl)methoxy]phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(difluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(2,2,2-trifluoroethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-[2-Chloro-6-(2,2-difluoroethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 2-[3-Chloro-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)phenoxy]acetonitrile; 5-[2-Chloro-6-(2,2-dimethylpropoxy)phenyl]-1,3-dihydrobenzimidazol-2-one; 5-(2-Benzyloxy-6-chloro-phenyl)-1,3-dihydrobenzimidazol-2-one; tert-Butyl 3-[3-chloro-2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)phenoxy]azetidine-1-carboxylate; 5-(2-Chloro-6-thiazol-5-yloxy-phenyl)-1,3-dihydrobenzimidazol-2-one; 5-[2-(2,2-Difluoroethoxy)-6-methoxy-phenyl]-1,3-dihydrobenzimidazol-2-one;
Assignees
Inventors
Classifications
linked by a carbon chain containing aromatic rings · CPC title
linked by a carbon chain containing aromatic rings · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
linked by a carbon chain containing aromatic rings · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10611730B2 cover?
- Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
- Who is the assignee on this patent?
- Janssen Pharmaceutica Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D235/26. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).